AstraZeneca PLC (AZN)vsWarby Parker Inc (WRBY)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
WRBY
Warby Parker Inc
$22.72
-5.80%
HEALTHCARE · Cap: $3.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6687% more annual revenue ($60.44B vs $890.57M). AZN leads profitability with a 17.2% profit margin vs 0.1%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
WRBY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-50.4%
Fair Value
$14.62
Current Price
$22.72
$8.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
ROE of 0.4% — below average capital efficiency
0.1% margin — thin
Operating margin of 0.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Operating Margin. A P/E of 2479.0x leaves little room for execution misses. Thin 0.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.96 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is a trendsetting leader in the direct-to-consumer eyewear market, established in 2010 with the mission to revolutionize the way consumers purchase eyewear through a seamless blend of online shopping and an expanding number of retail stores. The company is renowned for its stylish, affordable prescription glasses and sunglasses, appealing to a broad range of customers. Warby Parker's socially conscious business model, epitomized by its "Buy a Pair, Give a Pair" initiative, reflects a commitment to social responsibility by providing eyewear to those in need. With a robust brand reputation and a dedication to innovative marketing strategies, Warby Parker is well-positioned for ongoing growth and success in a competitive landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?